生物制剂与靶向合成改善病情抗风湿药治疗类风湿关节炎的超声疗效:日本多中心类风湿关节炎超声前瞻性队列研究
该前瞻性队列自2013年6月起在日本九州地区纳入活动性类风湿关节炎患者,在启用生物制剂或靶向合成改善病情抗风湿药后行超声随访,共150例完成前6个月观察。结果显示6个月时总PD与灰阶评分及临床复合指标均显著改善,但生物制剂转换者较初治者改善较少;多因素logistic回归显示短病程、既往未使用生物制剂及基线总PD评分低是6个月PD缓解的独立预测因素。
要点
- 6个月时总PD评分、灰阶评分及临床复合指标均显著改善。
- 生物制剂转换者的上述改善较生物制剂初治者少。
- 短病程、既往未用生物制剂、基线总PD评分低是6个月PD缓解的独立预测因素。
核心结论
- 该前瞻性超声队列首次展示了与生物制剂或靶向合成改善病情抗风湿药初始PD反应相关的变量。
研究设计与样本
- 前瞻性队列研究,自2013年6月起在日本九州地区纳入活动性类风湿关节炎患者,在引入生物制剂或靶向合成改善病情抗风湿药后行超声随访。
- 共150例患者完成前6个月观察并接受评估。
- 超声评估双侧手22个关节的灰阶与PD图像,采用0-3分评分,各评分之和作为超声疾病活动度指标。
- PD缓解定义为6个月时总PD评分为0,采用多因素logistic回归分析相关变量。
主要发现
- 6个月时总PD评分、灰阶评分及临床复合指标均显著改善。
- 上述改善在生物制剂转换者中较生物制剂初治者少。
- 多因素logistic回归分析显示,短病程、既往未使用生物制剂及基线总PD评分低是6个月PD缓解的独立预测因素。
关键数值与推荐
- PD缓解定义为6个月时总PD评分为0。
- 超声评估双侧手22个关节,灰阶与PD图像采用0-3分评分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the variables associated with initial favorable power Doppler (PD) ultrasound (US) response induced by biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in patients with rheumatoid arthritis (RA). METHODS: We have been prospectively investigating the course of active RA patients using US after the introduction of b/tsDMARDs in the Kyushu region of Japan since June 2013. A total of 150 patients have completed the first 6 months of observation at present and have been evaluated. US was assessed in 22 joints of bilateral hands using gray-scale and PD images on a scale from 0-3. The sum of these scores was used as the indicator of US disease activity. We defined PD remission as attaining a total PD score of 0 at 6 months and investigated the associated variables by multivariate logistic regression analysis. RESULTS: The total PD and gray-scale scores and the clinical composite measures significantly improved at 6 months, whereas these reductions were less in bDMARD switchers as compared with bDMARD-naive patients. Multivariate logistic regression analysis showed that short disease duration, the absence of any previous use of bDMARDs, and low total PD scores at baseline were independent predictors of PD remission at 6 months. CONCLUSION: This present prospective US cohort has for the first time shown the variables that are associated with initial PD response to b/tsDMARDs.
引用
- Nishino A, Kawashiri SY, Koga T, et al. Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan. Arthritis Care Res (Hoboken). 2018. PMID: 29481732. doi:10.1002/acr.23551
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。